The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer

S. Pignata; G. Scambia; D. Lorusso; U. De Giorgi; M. O. Nicoletto; R. Lauria; A. M. Mosconi; C. Sacco; C. Omarini; P. Tagliaferri; G. Ferrandina; S. Cinieri; A. Savarese; G. Valabrega; C. Pisano; V. Salutari; F. Raspagliesi; B. Kopf; S. C. Cecere; G. Amadio; G. Maltese; M. Di Napoli; S. Greggi; S. Signoriello; G. Daniele; A. Sacco; S. Losito; N. Normanno; F. Perrone; C. Gallo; M. C. Piccirillo; MITO Investigators

doi:10.1016/j.ygyno.2019.03.260

The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer

S. Pignata, G. Scambia, D. Lorusso, U. De Giorgi, M. O. Nicoletto, R. Lauria, A. M. Mosconi, C. Sacco, C. Omarini, P. Tagliaferri, G. Ferrandina, S. Cinieri, A. Savarese, G. Valabrega, C. Pisano, V. Salutari, F. Raspagliesi, B. Kopf, S. C. Cecere, G. AmadioG. Maltese, M. Di Napoli, S. Greggi, S. Signoriello, G. Daniele, A. Sacco, S. Losito, N. Normanno, F. Perrone, C. Gallo, M. C. Piccirillo, MITO Investigators

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Cervical cancer cells often express Epidermal Growth Factor Receptor (EGFR). Cetuximab (CET), an anti-EGFR antibody, can be safely combined with carboplatin (C) and paclitaxel (P), a standard treatment for advanced/recurrent cervical cancer (ARCC) patients. PATIENTS AND METHODS: ARCC patients, ECOG PS

Original language	Italian
Pages (from-to)	535-540
Number of pages	6
Journal	Gynecologic Oncology
Volume	153
Issue number	3
DOIs	https://doi.org/10.1016/j.ygyno.2019.03.260
Publication status	Published - 2019

Access to Document

10.1016/j.ygyno.2019.03.260

Cite this

Pignata, S., Scambia, G., Lorusso, D., De Giorgi, U., Nicoletto, M. O., Lauria, R., Mosconi, A. M., Sacco, C., Omarini, C., Tagliaferri, P., Ferrandina, G., Cinieri, S., Savarese, A., Valabrega, G., Pisano, C., Salutari, V., Raspagliesi, F., Kopf, B., Cecere, S. C., ... Investigators, MITO. (2019). The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. Gynecologic Oncology, 153(3), 535-540. https://doi.org/10.1016/j.ygyno.2019.03.260

The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. / Pignata, S.; Scambia, G.; Lorusso, D.; De Giorgi, U.; Nicoletto, M. O.; Lauria, R.; Mosconi, A. M.; Sacco, C.; Omarini, C.; Tagliaferri, P.; Ferrandina, G.; Cinieri, S.; Savarese, A.; Valabrega, G.; Pisano, C.; Salutari, V.; Raspagliesi, F.; Kopf, B.; Cecere, S. C.; Amadio, G.; Maltese, G.; Di Napoli, M.; Greggi, S.; Signoriello, S.; Daniele, G.; Sacco, A.; Losito, S.; Normanno, N.; Perrone, F.; Gallo, C.; Piccirillo, M. C.; Investigators, MITO.

In: Gynecologic Oncology, Vol. 153, No. 3, 2019, p. 535-540.

Research output: Contribution to journal › Article › peer-review

Pignata, S, Scambia, G, Lorusso, D, De Giorgi, U, Nicoletto, MO, Lauria, R, Mosconi, AM, Sacco, C, Omarini, C, Tagliaferri, P, Ferrandina, G, Cinieri, S, Savarese, A, Valabrega, G, Pisano, C, Salutari, V, Raspagliesi, F, Kopf, B, Cecere, SC, Amadio, G, Maltese, G, Di Napoli, M, Greggi, S, Signoriello, S, Daniele, G, Sacco, A, Losito, S, Normanno, N, Perrone, F, Gallo, C, Piccirillo, MC & Investigators, MITO 2019, 'The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer', Gynecologic Oncology, vol. 153, no. 3, pp. 535-540. https://doi.org/10.1016/j.ygyno.2019.03.260

Pignata, S. ; Scambia, G. ; Lorusso, D. ; De Giorgi, U. ; Nicoletto, M. O. ; Lauria, R. ; Mosconi, A. M. ; Sacco, C. ; Omarini, C. ; Tagliaferri, P. ; Ferrandina, G. ; Cinieri, S. ; Savarese, A. ; Valabrega, G. ; Pisano, C. ; Salutari, V. ; Raspagliesi, F. ; Kopf, B. ; Cecere, S. C. ; Amadio, G. ; Maltese, G. ; Di Napoli, M. ; Greggi, S. ; Signoriello, S. ; Daniele, G. ; Sacco, A. ; Losito, S. ; Normanno, N. ; Perrone, F. ; Gallo, C. ; Piccirillo, M. C. ; Investigators, MITO. / The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. In: Gynecologic Oncology. 2019 ; Vol. 153, No. 3. pp. 535-540.

@article{40539630774c4c2db43319c046e1f982,

title = "The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer",

abstract = "BACKGROUND: Cervical cancer cells often express Epidermal Growth Factor Receptor (EGFR). Cetuximab (CET), an anti-EGFR antibody, can be safely combined with carboplatin (C) and paclitaxel (P), a standard treatment for advanced/recurrent cervical cancer (ARCC) patients. PATIENTS AND METHODS: ARCC patients, ECOG PS",

keywords = "Cervical cancer, Cetuximab, PIK3CA mutation, Randomized phase 2",

author = "S. Pignata and G. Scambia and D. Lorusso and {De Giorgi}, U. and Nicoletto, {M. O.} and R. Lauria and Mosconi, {A. M.} and C. Sacco and C. Omarini and P. Tagliaferri and G. Ferrandina and S. Cinieri and A. Savarese and G. Valabrega and C. Pisano and V. Salutari and F. Raspagliesi and B. Kopf and Cecere, {S. C.} and G. Amadio and G. Maltese and {Di Napoli}, M. and S. Greggi and S. Signoriello and G. Daniele and A. Sacco and S. Losito and N. Normanno and F. Perrone and C. Gallo and Piccirillo, {M. C.} and MITO Investigators",

note = "LR: 20190413; CI: Copyright (c) 2019; JID: 0365304; OTO: NOTNLM; 2019/03/05 00:00 [received]; 2019/03/28 00:00 [revised]; 2019/03/31 00:00 [accepted]; 2019/04/14 06:00 [entrez]; 2019/04/14 06:00 [pubmed]; 2019/04/14 06:00 [medline]; aheadofprint M1 - Journal Article",

year = "2019",

doi = "10.1016/j.ygyno.2019.03.260",

language = "Italian",

volume = "153",

pages = "535--540",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer

AU - Pignata, S.

AU - Scambia, G.

AU - Lorusso, D.

AU - De Giorgi, U.

AU - Nicoletto, M. O.

AU - Lauria, R.

AU - Mosconi, A. M.

AU - Sacco, C.

AU - Omarini, C.

AU - Tagliaferri, P.

AU - Ferrandina, G.

AU - Cinieri, S.

AU - Savarese, A.

AU - Valabrega, G.

AU - Pisano, C.

AU - Salutari, V.

AU - Raspagliesi, F.

AU - Kopf, B.

AU - Cecere, S. C.

AU - Amadio, G.

AU - Maltese, G.

AU - Di Napoli, M.

AU - Greggi, S.

AU - Signoriello, S.

AU - Daniele, G.

AU - Sacco, A.

AU - Losito, S.

AU - Normanno, N.

AU - Perrone, F.

AU - Gallo, C.

AU - Piccirillo, M. C.

AU - Investigators, MITO

N1 - LR: 20190413; CI: Copyright (c) 2019; JID: 0365304; OTO: NOTNLM; 2019/03/05 00:00 [received]; 2019/03/28 00:00 [revised]; 2019/03/31 00:00 [accepted]; 2019/04/14 06:00 [entrez]; 2019/04/14 06:00 [pubmed]; 2019/04/14 06:00 [medline]; aheadofprint M1 - Journal Article

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Cervical cancer cells often express Epidermal Growth Factor Receptor (EGFR). Cetuximab (CET), an anti-EGFR antibody, can be safely combined with carboplatin (C) and paclitaxel (P), a standard treatment for advanced/recurrent cervical cancer (ARCC) patients. PATIENTS AND METHODS: ARCC patients, ECOG PS

AB - BACKGROUND: Cervical cancer cells often express Epidermal Growth Factor Receptor (EGFR). Cetuximab (CET), an anti-EGFR antibody, can be safely combined with carboplatin (C) and paclitaxel (P), a standard treatment for advanced/recurrent cervical cancer (ARCC) patients. PATIENTS AND METHODS: ARCC patients, ECOG PS

KW - Cervical cancer

KW - Cetuximab

KW - PIK3CA mutation

KW - Randomized phase 2

U2 - 10.1016/j.ygyno.2019.03.260

DO - 10.1016/j.ygyno.2019.03.260

M3 - Articolo

VL - 153

SP - 535

EP - 540

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -